Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29155
Full metadata record
DC FieldValueLanguage
dc.contributor.authorComi, G.-
dc.contributor.authorArnold, D. L.-
dc.contributor.authorBoyko, A. N.-
dc.contributor.authorHartung, H. -P.-
dc.contributor.authorHavrdova, E. K.-
dc.contributor.authorInshasi, J. S.-
dc.contributor.authorMcCombe, P.-
dc.contributor.authorNakamura, K.-
dc.contributor.authorOreja-Guevara, C.-
dc.contributor.authorPelletier, D.-
dc.contributor.authorPozzilli, C.-
dc.contributor.authorSelmaj, K. W.-
dc.contributor.authorScott, T. F.-
dc.contributor.authorChung, L.-
dc.contributor.authorDaizadeh, N.-
dc.contributor.authorAfsar, S.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.date.accessioned2019-09-12T10:52:01Z-
dc.date.available2019-09-12T10:52:01Z-
dc.date.issued2019-
dc.identifier.citationEUROPEAN JOURNAL OF NEUROLOGY, 26(SI), p. 30-30-
dc.identifier.issn1351-5101-
dc.identifier.urihttp://hdl.handle.net/1942/29155-
dc.description.sponsorshipSanofi and Bayer HealthCare Pharmaceuticals.-
dc.language.isoen-
dc.publisherWILEY-
dc.titleAlemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateJUN 29-JUL 02, 2019-
local.bibliographicCitation.conferencename5th Congress of the European-Academy-of-Neurology (EAN)-
local.bibliographicCitation.conferenceplaceOslo, NORWAY-
dc.identifier.epage30-
dc.identifier.issueSI-
dc.identifier.spage30-
dc.identifier.volume26-
local.format.pages1-
local.bibliographicCitation.jcatM-
dc.description.notes[Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Arnold, D. L.] NeuroRx Res, Montreal, PQ, Canada. [Boyko, A. N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, A. N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [Hartung, H. -P.] Heinrich Heine Univ, Dusseldorf, Germany. [Havrdova, E. K.] Charles Univ Prague, Med Fac 1, Prague, Czech Republic. [Inshasi, J. S.] Rashid Hosp, Dubai, U Arab Emirates. [Inshasi, J. S.] Dubai Med Coll, Dubai, U Arab Emirates. [McCombe, P.] Univ Queensland, Brisbane, Qld, Australia. [Nakamura, K.] Cleveland Clin, Cleveland, OH 44106 USA. [Oreja-Guevara, C.] Univ Hosp San Carlos, Madrid, Spain. [Pelletier, D.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA. [Pozzilli, C.] Univ Rome, Rome, Italy. [Selmaj, K. W.] Univ Warmia & Mazury, Olsztyn, Poland. [Scott, T. F.] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA. [Chung, L.; Daizadeh, N.; Afsar, S.] Sanofi, Cambridge, MA USA. [Van Wijmeersch, B.] Hasselt Univ, BIOMED, Rehabil & MS Ctr Overpelt, Hasselt, Belgium.-
local.publisher.placeHOBOKEN-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isi000474481000048-
item.fullcitationComi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H. -P.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S. & VAN WIJMEERSCH, Bart (2019) Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study). In: EUROPEAN JOURNAL OF NEUROLOGY, 26(SI), p. 30-30.-
item.contributorComi, G.-
item.contributorArnold, D. L.-
item.contributorBoyko, A. N.-
item.contributorHartung, H. -P.-
item.contributorHavrdova, E. K.-
item.contributorInshasi, J. S.-
item.contributorMcCombe, P.-
item.contributorNakamura, K.-
item.contributorOreja-Guevara, C.-
item.contributorPelletier, D.-
item.contributorPozzilli, C.-
item.contributorSelmaj, K. W.-
item.contributorScott, T. F.-
item.contributorChung, L.-
item.contributorDaizadeh, N.-
item.contributorAfsar, S.-
item.contributorVAN WIJMEERSCH, Bart-
item.accessRightsClosed Access-
item.fulltextNo Fulltext-
crisitem.journal.issn1351-5101-
crisitem.journal.eissn1468-1331-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.